Can rosuvastatin cause worsening depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Rosuvastatin and Depression: Clinical Guidance

Rosuvastatin does not cause worsening depression in most patients and may actually have protective effects against depression, though rare cases of mood disturbances have been documented. The FDA label lists depression as a postmarketing adverse reaction, but large-scale evidence suggests statins, including rosuvastatin, are more likely to reduce depression risk than increase it 1.

Evidence Summary

FDA-Approved Safety Information

The FDA drug label for rosuvastatin explicitly lists depression under psychiatric disorders as a postmarketing adverse reaction, along with sleep disorders (including insomnia and nightmares) 1. However, these reports are voluntary from an uncertain population size, making frequency estimation and causal relationship difficult to establish definitively.

Large-Scale Evidence Shows Protective Effects

The most robust evidence suggests statins reduce depression risk rather than worsen it. A 2025 meta-analysis of 15 studies involving over 5.4 million participants found that statin use was associated with significantly lower depression risk (OR = 0.84,95% CI: 0.74-0.96, p = 0.009) 2. This protective effect was particularly evident in:

  • Patients with comorbidities (OR = 0.74)
  • Those concurrently using anti-inflammatory or antidepressant drugs (OR = 0.82)
  • North American populations (OR = 0.63)

Contradictory Evidence: Case Reports of Mood Changes

Despite the favorable population-level data, individual case reports document mood disturbances with rosuvastatin:

  • A 2016 case series reported violent ideation, irritability, and depression in patients on various statins, including one case involving rosuvastatin combined with fenofibrate that led to aggression/irritability within 1 month (Naranjo score: probable causality) 3
  • A 2025 case report described mood disturbances with atorvastatin (Naranjo score: 8, indicating probable relationship) that resolved upon discontinuation 4

Importantly, a 2020 randomized controlled trial (YoDA-A) in young people with moderate-to-severe depression found that adjunctive rosuvastatin did not significantly improve depressive symptoms compared to placebo at 12 weeks (difference: -4.2,95% CI: -9.1 to 0.6, p = 0.089) 5.

Clinical Approach

Risk Assessment

Monitor for mood changes in patients with these risk factors:

  • Pre-existing psychiatric history (though mood changes can occur even without prior history) 4
  • Low baseline cholesterol levels 6
  • Concurrent use of multiple medications affecting brain cholesterol
  • Genetic variants affecting brain-derived neurotrophic factor (particularly in patients with schizophrenia) 7

Monitoring Strategy

  • Screen for depressive symptoms at baseline before initiating rosuvastatin
  • Reassess mood at 2-4 weeks after initiation (when most case reports show symptom onset) 3, 4
  • Ask specifically about: irritability, aggressive thoughts, sleep disturbances, mood changes
  • If mood symptoms emerge, consider temporal relationship to statin initiation

Management of Suspected Mood Changes

If depression worsens or new mood symptoms develop:

  1. Discontinue rosuvastatin temporarily - Most case reports show rapid resolution (days to weeks) upon discontinuation 3, 4

  2. Assess for alternative causes:

    • Stress and anxiety (strongest predictors of depression in diabetic patients on statins) 8
    • Concurrent medication changes
    • Life stressors or medical comorbidities

  3. Consider rechallenge cautiously if cardiovascular benefit is substantial:

    • Use lower dose or different statin
    • The Canadian guideline notes 92% of patients with statin-related events tolerated rechallenge at 12 months 7
    • Fluvastatin or lovastatin may have lower risk profiles 7

  4. If mood symptoms recur with rechallenge, this strongly suggests causality - permanently discontinue and use alternative lipid-lowering therapy (ezetimibe, PCSK9 inhibitors, bempedoic acid)

Key Caveats

  • The absolute risk is very low - population studies show protective effects, but individual susceptibility exists
  • Do not withhold statins based solely on depression concerns in patients with clear cardiovascular indications - the mortality benefit typically outweighs psychiatric risk 7
  • Distinguish between correlation and causation - patients with cardiovascular disease have higher baseline depression rates independent of statin use
  • The mechanism may involve reduced brain cholesterol affecting serotonergic neurotransmission 6, 9, but this same mechanism may also explain potential antidepressant effects through anti-inflammatory pathways 9

In patients with established depression requiring statins, the evidence favors continuation with close monitoring rather than avoidance 2, 9.

References

Related Questions

Can atorvastatin (HMG-CoA reductase inhibitor) cause mood changes?
Can Rosuvastatin (statin) cause emotional rage in patients?
Compare the two laboratory panels (first: glucose 163 mg/dL, blood urea nitrogen 29 mg/dL, creatinine 0.6 mg/dL, BUN‑to‑creatinine ratio 50, sodium 130 mmol/L, potassium 4.4 mmol/L, chloride 97 mmol/L, CO₂ 27 mmol/L, calcium 8.9 mg/dL, estimated glomerular filtration rate >90 mL/min/1.73 m²; second: glucose 184 mg/dL, blood urea nitrogen 26 mg/dL, creatinine 0.5 mg/dL, BUN‑to‑creatinine ratio 55, sodium 135 mmol/L, potassium 4.3 mmol/L, chloride 103 mmol/L, CO₂ 25 mmol/L, calcium 9.2 mg/dL, estimated glomerular filtration rate >90 mL/min/1.73 m²) to assess dehydration?
How should aplastic anemia be managed with eltrombopag (Promacta) and cyclosporine?
What is the first-line management for a patient with chronic venous insufficiency?
Given two sets of labs showing hyperglycemia, markedly elevated blood urea nitrogen with a very high BUN/creatinine ratio, mild hyponatremia, low‑normal chloride, normal potassium, CO₂, calcium, and preserved estimated glomerular filtration rate, what is the most likely diagnosis and what immediate management steps should be taken?
What are the possible causes of fever with chills and cough followed by diarrhea and vomiting?
What is the recommended clonidine dosing schedule, duration, and monitoring parameters for an adult patient with opioid withdrawal who is medically stable and not taking other centrally acting antihypertensives?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.